BLD-2660
/ Blade Therap
- LARVOL DELTA
Home
Next
Prev
1 to 16
Of
16
Go to page
1
April 06, 2022
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects
(clinicaltrials.gov)
- P2 | N=120 | Completed | Sponsor: Blade Therapeutics | Active, not recruiting ➔ Completed | Trial completion date: Nov 2021 ➔ Jun 2021
Trial completion • Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
February 17, 2021
Small-molecule antiviral agents in ongoing clinical trials for COVID-19.
(PubMed, Curr Drug Targets)
- "These include viral polymerase and protease inhibitors remdesivir, galidesivir, favipiravir, ribavirin, sofosbuvir, tenofovir/emtricitabine, baloxavir marboxil, EIDD-2801, lopinavir/ritonavir; virus-/host-directed viral entry and fusion inhibitors arbidol chloroquine/hydroxychloroquine, chlorpromazine, camostat mesylate, nafamostat mesylate, bromhexine and agents with diverse/unclear mechanism of actions as oseltamivir, triazavirin, ivermectin, nitazoxanide, niclosamide and BLD-2660. The published preclinical and clinical data to date on these drugs as well as the mechanisms of action are reviewed."
Clinical • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
March 04, 2021
Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF
(clinicaltrials.gov)
- P2a; N=0; Withdrawn; Sponsor: Blade Therapeutics; N=32 ➔ 0; Trial completion date: May 2021 ➔ Nov 2020; Suspended ➔ Withdrawn; Trial primary completion date: Mar 2021 ➔ Sep 2020
Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Respiratory Diseases • EZR • S100A9 • Spectrin
February 23, 2021
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects
(clinicaltrials.gov)
- P2; N=120; Active, not recruiting; Sponsor: Blade Therapeutics; Trial completion date: Nov 2020 ➔ Nov 2021
Clinical • Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
October 30, 2020
Healthy Volunteer Study Comparing Tablet and Capsule Formulations
(clinicaltrials.gov)
- P1; N=0; Withdrawn; Sponsor: Blade Therapeutics; N=34 ➔ 0; Not yet recruiting ➔ Withdrawn
Clinical • Enrollment change • Trial withdrawal • Fibrosis • Immunology
October 30, 2020
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects
(clinicaltrials.gov)
- P2; N=120; Active, not recruiting; Sponsor: Blade Therapeutics; Recruiting ➔ Active, not recruiting
Clinical • Enrollment closed • Infectious Disease • Novel Coronavirus Disease
September 14, 2020
Blade Therapeutics Reaches Enrollment Goal for Phase 2 Study of Lead Investigational Therapy BLD-2660 in Treating Patients With COVID-19 Pneumonia
(Businesswire)
- "Blade Therapeutics today announced that it has reached the 120-subject enrollment goal for the Phase 2 clinical study of the Company’s investigational therapeutic, BLD-2660....Independent Data Monitoring Committee (DMC) recommended continuation of the trial without changes after conducting a planned review of blinded safety data....'We look forward to topline results in 4Q-2020.'"
DSMB • Enrollment closed • P2 data • Infectious Disease • Novel Coronavirus Disease
September 03, 2020
Healthy Volunteer Study Comparing Tablet and Capsule Formulations
(clinicaltrials.gov)
- P1; N=34; Not yet recruiting; Sponsor: Blade Therapeutics; Trial completion date: Nov 2019 ➔ Jul 2021; Trial primary completion date: Oct 2019 ➔ Jun 2021
Clinical • Trial completion date • Trial primary completion date • Fibrosis • Immunology
September 03, 2020
Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF
(clinicaltrials.gov)
- P2a; N=32; Suspended; Sponsor: Blade Therapeutics; Trial completion date: Dec 2020 ➔ May 2021; Initiation date: Apr 2020 ➔ Nov 2020; Not yet recruiting ➔ Suspended; Trial primary completion date: Aug 2020 ➔ Mar 2021
Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Trial suspension • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Respiratory Diseases • EZR • S100A9 • Spectrin
August 12, 2020
Blade Therapeutics Updates Enrollment Progress for Phase 2 Study of Lead Investigational Therapy BLD-2660 in Treating Patients with COVID-19 Pneumonia
(Businesswire)
- "Blade Therapeutics today announced that the Phase 2 clinical study of the company’s investigational therapeutic, BLD-2660, has enrolled half of the anticipated 120 coronavirus disease-19 (COVID-19) pneumonia patients....The trial permits concomitant use of approved therapeutics including Remdesivir....'The timeline remains on track. We expect to complete enrollment in 3Q-2020 and provide topline results in 4Q-2020.'"
Enrollment status • P2 data • Infectious Disease • Novel Coronavirus Disease
July 27, 2020
Sorocabanos will test new medication in the treatment of Covid-19 [Google translation]
(Jornal Cruzeiro do Sul)
- "Sorocaba coronavirus patients will volunteer in a clinical research study to test the efficacy or otherwise of leading-edge drugs in the treatment of Covid-19. The unprecedented scientific work is being carried out in at least 40 hospitals worldwide....Of the five drugs that patients will receive, three already exist....They are: Ruxolitinib, Acalabrutinib and Lenzilumab (Humanigen). Two other drugs do not yet exist on the market and are called ANG-3777 (Angion) and BLD-2660 (Blade)."
Trial status • Infectious Disease • Novel Coronavirus Disease
May 08, 2020
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects
(clinicaltrials.gov)
- P2; N=120; Recruiting; Sponsor: Blade Therapeutics; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open
April 06, 2020
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects
(clinicaltrials.gov)
- P2; N=120; Not yet recruiting; Sponsor: Blade Therapeutics
Clinical • New P2 trial
March 18, 2020
First in Human Study in Healthy Volunteers Followed With Dosing in Participants With Lung or Liver Fibrosis
(clinicaltrials.gov)
- P1a/1b; N=88; Completed; Sponsor: Blade Therapeutics; Recruiting ➔ Completed
Clinical • Trial completion
January 28, 2020
Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF
(clinicaltrials.gov)
- P2a; N=32; Not yet recruiting; Sponsor: Blade Therapeutics
New P2a trial • EZR • Spectrin
November 26, 2019
Blade Therapeutics to present at the 31st Annual Piper Jaffray Healthcare Conference
(Yahoo Finance)
- "BLD-2660 recently completed a Phase I, healthy volunteer, dose escalation study in Australia. The Company plans to initiate a Phase II trial in patients with idiopathic pulmonary fibrosis in early 2020."
New P2 trial • Trial completion
1 to 16
Of
16
Go to page
1